3.23.2 html 137 170 1 false 31 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.moleculin.com/20230630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.moleculin.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.moleculin.com/20230630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.moleculin.com/20230630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.moleculin.com/20230630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statement of Stockholders Equity (Unaudited) Sheet http://www.moleculin.com/20230630/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited Condensed Consolidated Statement of Stockholders Equity (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Business Sheet http://www.moleculin.com/20230630/role/statement-note-1-nature-of-business Note 1 - Nature of Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity Sheet http://www.moleculin.com/20230630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Warrants Sheet http://www.moleculin.com/20230630/role/statement-note-3-warrants Note 3 - Warrants Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Equity Sheet http://www.moleculin.com/20230630/role/statement-note-4-equity Note 4 - Equity Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Income Taxes Sheet http://www.moleculin.com/20230630/role/statement-note-5-income-taxes Note 5 - Income Taxes Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Commitments and Contingencies Sheet http://www.moleculin.com/20230630/role/statement-note-6-commitments-and-contingencies Note 6 - Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Subsequent Events Sheet http://www.moleculin.com/20230630/role/statement-note-7-subsequent-events Note 7 - Subsequent Events Notes 13 false false R14.htm 013 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.moleculin.com/20230630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.moleculin.com/20230630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity 14 false false R15.htm 014 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Tables) Sheet http://www.moleculin.com/20230630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Tables) Tables http://www.moleculin.com/20230630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity 15 false false R16.htm 015 - Disclosure - Note 3 - Warrants (Tables) Sheet http://www.moleculin.com/20230630/role/statement-note-3-warrants-tables Note 3 - Warrants (Tables) Tables http://www.moleculin.com/20230630/role/statement-note-3-warrants 16 false false R17.htm 016 - Disclosure - Note 4 - Equity (Tables) Sheet http://www.moleculin.com/20230630/role/statement-note-4-equity-tables Note 4 - Equity (Tables) Tables http://www.moleculin.com/20230630/role/statement-note-4-equity 17 false false R18.htm 017 - Disclosure - Note 6 - Commitments and Contingencies (Tables) Sheet http://www.moleculin.com/20230630/role/statement-note-6-commitments-and-contingencies-tables Note 6 - Commitments and Contingencies (Tables) Tables http://www.moleculin.com/20230630/role/statement-note-6-commitments-and-contingencies 18 false false R19.htm 018 - Disclosure - Note 1 - Nature of Business (Details Textual) Sheet http://www.moleculin.com/20230630/role/statement-note-1-nature-of-business-details-textual Note 1 - Nature of Business (Details Textual) Details http://www.moleculin.com/20230630/role/statement-note-1-nature-of-business 19 false false R20.htm 019 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Details Textual) Sheet http://www.moleculin.com/20230630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Details Textual) Details http://www.moleculin.com/20230630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables 20 false false R21.htm 020 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.moleculin.com/20230630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) Details 21 false false R22.htm 021 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) Sheet http://www.moleculin.com/20230630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) Details 22 false false R23.htm 022 - Disclosure - Note 3 - Warrants (Details Textual) Sheet http://www.moleculin.com/20230630/role/statement-note-3-warrants-details-textual Note 3 - Warrants (Details Textual) Details http://www.moleculin.com/20230630/role/statement-note-3-warrants-tables 23 false false R24.htm 023 - Disclosure - Note 3 - Warrants - Assumptions Used (Details) Sheet http://www.moleculin.com/20230630/role/statement-note-3-warrants-assumptions-used-details Note 3 - Warrants - Assumptions Used (Details) Details 24 false false R25.htm 024 - Disclosure - Note 3 - Warrants - Warrant Activity (Details) Sheet http://www.moleculin.com/20230630/role/statement-note-3-warrants-warrant-activity-details Note 3 - Warrants - Warrant Activity (Details) Details 25 false false R26.htm 025 - Disclosure - Note 4 - Equity (Details Textual) Sheet http://www.moleculin.com/20230630/role/statement-note-4-equity-details-textual Note 4 - Equity (Details Textual) Details http://www.moleculin.com/20230630/role/statement-note-4-equity-tables 26 false false R27.htm 026 - Disclosure - Note 4 - Equity - Stock based Compensation (Details) Sheet http://www.moleculin.com/20230630/role/statement-note-4-equity-stock-based-compensation-details Note 4 - Equity - Stock based Compensation (Details) Details 27 false false R28.htm 027 - Disclosure - Note 5 - Income Taxes (Details Textual) Sheet http://www.moleculin.com/20230630/role/statement-note-5-income-taxes-details-textual Note 5 - Income Taxes (Details Textual) Details http://www.moleculin.com/20230630/role/statement-note-5-income-taxes 28 false false R29.htm 028 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) Sheet http://www.moleculin.com/20230630/role/statement-note-6-commitments-and-contingencies-details-textual Note 6 - Commitments and Contingencies (Details Textual) Details http://www.moleculin.com/20230630/role/statement-note-6-commitments-and-contingencies-tables 29 false false R30.htm 029 - Disclosure - Note 6 - Commitments and Contingencies - Lease Cost (Details) Sheet http://www.moleculin.com/20230630/role/statement-note-6-commitments-and-contingencies-lease-cost-details Note 6 - Commitments and Contingencies - Lease Cost (Details) Details 30 false false R31.htm 030 - Disclosure - Note 7 - Subsequent Events (Details Textual) Sheet http://www.moleculin.com/20230630/role/statement-note-7-subsequent-events-details-textual Note 7 - Subsequent Events (Details Textual) Details http://www.moleculin.com/20230630/role/statement-note-7-subsequent-events 31 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 35 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, mbrx:LicenseTerminationsExpense, mbrx:NumberOfCoreDrugTechnologies, mbrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentPeriods, us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EffectiveIncomeTaxRateContinuingOperations, us-gaap:IncomeTaxExpenseBenefit, us-gaap:NumberOfOperatingSegments, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:RelatedPartyTransactionAmountsOfTransaction, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:WarrantsAndRightsOutstandingTerm - mbrx20230515_10q.htm 8, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 mbrx20230515_10q.htm ex_521676.htm ex_521677.htm ex_521678.htm ex_521679.htm mbrx-20230630.xsd mbrx-20230630_cal.xml mbrx-20230630_def.xml mbrx-20230630_lab.xml mbrx-20230630_pre.xml moleculinnewlogoresized.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true